Cipher Pharmaceuticals (CPHR) Getting Somewhat Favorable News Coverage, Study Finds

News stories about Cipher Pharmaceuticals (NASDAQ:CPHR) (TSE:CPH) have been trending somewhat positive on Friday, according to AlphaOne Sentiment. The research firm, a unit of Accern, ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cipher Pharmaceuticals earned a news sentiment score of 0.21 on AlphaOne’s scale. AlphaOne also assigned news articles about the company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the company’s share price in the near future.

Cipher Pharmaceuticals (NASDAQ:CPHR) traded up 0.0000% during midday trading on Friday, reaching $2.9901. Cipher Pharmaceuticals has a one year low of $2.55 and a one year high of $6.25. The firm has a 50 day moving average of $2.99 and a 200 day moving average of $3.00.

ILLEGAL ACTIVITY NOTICE: “Cipher Pharmaceuticals (CPHR) Getting Somewhat Favorable News Coverage, Study Finds” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.

5 Day Chart for NASDAQ:CPHR

Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply